{
  "disease": "glioblastoma",
  "date_generated": "2026-02-14",
  "drugs_screened": [
    "TALAMPANEL",
    "RIVOCERANIB",
    "GENISTEIN",
    "EDOTECARIN",
    "CEDIRANIB",
    "PERIFOSINE"
  ],
  "events_used": [
    "GLIOBLASTOMA",
    "GLIOBLASTOMA MULTIFORME",
    "BRAIN NEOPLASM MALIGNANT",
    "BRAIN CANCER"
  ],
  "total_faers_reports": 20006989,
  "tests_run": 24,
  "correction_method": "fdr",
  "alpha": 0.05,
  "inverse_signals_found": 0,
  "positive_signals_found": 0,
  "summary": "All 6 drugs have INSUFFICIENT DATA for glioblastoma-specific FAERS analysis. This is expected for rare diseases like glioblastoma where co-occurrence of drug + disease event is extremely low. No protective or risk signals detected.",
  "results": {
    "TALAMPANEL": {
      "drug_total_reports": 0,
      "has_inverse_signal": false,
      "has_positive_signal": false,
      "best_event": "GLIOBLASTOMA",
      "report_count": 0,
      "ror": null,
      "ci_lower": null,
      "ci_upper": null,
      "p_value": null,
      "q_value": 1.0,
      "interpretation": "Insufficient data (a=0, b=0, c=1574, d=20005415). Need ≥3 co-reports for stable estimate.",
      "normalized_score": 0.0,
      "contingency_table": {
        "a": 0,
        "b": 0,
        "c": 1574,
        "d": 20005415
      }
    },
    "RIVOCERANIB": {
      "drug_total_reports": 94,
      "has_inverse_signal": false,
      "has_positive_signal": false,
      "best_event": "GLIOBLASTOMA",
      "report_count": 0,
      "ror": null,
      "ci_lower": null,
      "ci_upper": null,
      "p_value": null,
      "q_value": 1.0,
      "interpretation": "Insufficient data (a=0, b=94, c=1574, d=20005321). Need ≥3 co-reports for stable estimate.",
      "normalized_score": 0.0,
      "contingency_table": {
        "a": 0,
        "b": 94,
        "c": 1574,
        "d": 20005321
      }
    },
    "GENISTEIN": {
      "drug_total_reports": 66,
      "has_inverse_signal": false,
      "has_positive_signal": false,
      "best_event": "GLIOBLASTOMA",
      "report_count": 0,
      "ror": null,
      "ci_lower": null,
      "ci_upper": null,
      "p_value": null,
      "q_value": 1.0,
      "interpretation": "Insufficient data (a=0, b=66, c=1574, d=20005349). Need ≥3 co-reports for stable estimate.",
      "normalized_score": 0.0,
      "contingency_table": {
        "a": 0,
        "b": 66,
        "c": 1574,
        "d": 20005349
      }
    },
    "EDOTECARIN": {
      "drug_total_reports": 3,
      "has_inverse_signal": false,
      "has_positive_signal": false,
      "best_event": "GLIOBLASTOMA",
      "report_count": 0,
      "ror": null,
      "ci_lower": null,
      "ci_upper": null,
      "p_value": null,
      "q_value": 1.0,
      "interpretation": "Insufficient data (a=0, b=3, c=1574, d=20005412). Need ≥3 co-reports for stable estimate.",
      "normalized_score": 0.0,
      "contingency_table": {
        "a": 0,
        "b": 3,
        "c": 1574,
        "d": 20005412
      }
    },
    "CEDIRANIB": {
      "drug_total_reports": 119,
      "has_inverse_signal": false,
      "has_positive_signal": false,
      "best_event": "GLIOBLASTOMA",
      "report_count": 1,
      "ror": null,
      "ci_lower": null,
      "ci_upper": null,
      "p_value": null,
      "q_value": 1.0,
      "interpretation": "Insufficient data (a=1, b=118, c=1573, d=20005297). Need ≥3 co-reports for stable estimate.",
      "normalized_score": 0.0,
      "contingency_table": {
        "a": 1,
        "b": 118,
        "c": 1573,
        "d": 20005297
      },
      "notes": "Only 1 co-report with glioblastoma - too few for statistical inference but shows drug has been used in GBM patients."
    },
    "PERIFOSINE": {
      "drug_total_reports": 29,
      "has_inverse_signal": false,
      "has_positive_signal": false,
      "best_event": "GLIOBLASTOMA",
      "report_count": 1,
      "ror": null,
      "ci_lower": null,
      "ci_upper": null,
      "p_value": null,
      "q_value": 1.0,
      "interpretation": "Insufficient data (a=1, b=28, c=1573, d=20005387). Need ≥3 co-reports for stable estimate.",
      "normalized_score": 0.0,
      "contingency_table": {
        "a": 1,
        "b": 28,
        "c": 1573,
        "d": 20005387
      },
      "notes": "Only 1 co-report with glioblastoma - too few for statistical inference."
    }
  },
  "interpretation": "FAERS is not useful for glioblastoma repurposing due to disease rarity. The 1574 total glioblastoma reports in 20M+ total reports (~0.008%) make co-occurrence with any specific drug statistically underpowered. This is a limitation of the FAERS approach for rare diseases, NOT a weakness of these candidates.",
  "advocate_note": "The absence of adverse signals does not undermine these candidates. FAERS requires high report volumes that rare diseases cannot provide.",
  "skeptic_note": "The absence of protective signals means FAERS provides no positive evidence for repurposing, only a neutral baseline."
}
